LENZ Therapeutics Stock (NASDAQ:LENZ)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$6.58

52W Range

$6.29 - $50.40

50D Avg

$8.55

200D Avg

$20.85

Market Cap

$203.80M

Avg Vol (3M)

$926.46K

Beta

1.47

Div Yield

$7.21

LENZ Company Profile

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 22, 2024

Website

LENZ Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25
Product	$1.59M
License	$17.50M

Fiscal year ends in Dec 25 | Currency in USD

LENZ Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$19.09M	-	-
Operating Income	$-91.14M	$-58.61M	$-72.43M
Net Income	$-82.13M	$-49.77M	$-69.97M
EBITDA	$-91.14M	$-49.71M	$-72.41M
Basic EPS	$-2.85	$-2.34	$-15.30
Diluted EPS	$-2.85	$-2.34	$-15.30

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 24, 26 | 8:30 AM

Q3 25Nov 05, 25 | 8:30 AM

Q1 25May 09, 25 | 4:30 PM

Peer Comparison

Ticker	Company
NBTX	Nanobiotix S.A.
SPRY	ARS Pharmaceuticals, Inc.
ABUS	Arbutus Biopharma Corporation
RZLT	Rezolute, Inc.
GHRS	GH Research PLC
TYRA	Tyra Biosciences, Inc.
PRME	Prime Medicine, Inc.
MRVI	Maravai LifeSciences Holdings, Inc.
SVRA	Savara Inc.
GERN	Geron Corporation